Shares of Dendreon are off over 2% today despite an overall flat market. And down 12% in the past week despite the S&P being down about 0.4%. But even more importantly, shares of DNDN, currently at 34 and change are off 23 points from …
I like smarter guys than me to do the earlier heavy lifting. So I look for good successful investors who are also buying the stock. When it comes to DNDN that's easy. According to recent filing there are at least 4 super billionaire investors …
NEW YORK (CNNMoney.com) -- Dendreon's stock price surged immediately after the open of Friday trading, following an surprise positive vote from FDA advisors the day before, which favored the experimental prostate cancer treatment …
And while predicting Dendreon's stock price has been the most difficult aspect of this story, anyone following along with the Dendreon stock and option plays in our Biotech Stock Research Model Portfolio have banked significant returns despite …
NEW YORK (Reuters) - A lightening fast sell-off of shares of biotech company Dendreon last April is drawing scrutiny from U.S. securities regulators and the independent monitor assigned to keep tabs on those regulators, said people familiar …
J.P. Morgan (NYSE: JPM) has a $46 price target on the shares. During the last 52 weeks, Dendreon's stock has traded from a low of $2.55 to a high of $33.85. There are few signs that the momentum in this name will not continue. If their …
Shares of the drugmaker Dendreon are plummeting in trading, a day after the company announced a restructuring that includes closing a Morris County manufacturing plant. The Seattle-based company saw its stock slide more than 22 …
In fact, quite a few options players maintain a skeptical attitude toward DNDN. The stock's Schaeffer's put/call open interest ratio (SOIR) arrives at 0.97, in the 84th annual percentile. In other words, short-term speculators have been …
NEW YORK, April 14 (Reuters) - An experimental medicine from Dendreon Corp improved survival in men with advanced forms of prostate cancer, the company said on Tuesday, bolstering chances of it becoming the first approved …
Medicare is covering the vaccine now.The issue is so sensitive that trading in Dendreon's stock was halted Wednesday morning. It rose almost 8% to $38.64 in morning trading Thursday. The stock is down 11% in the past six months, …